BidaskClub upgraded shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.
ICPT has been the topic of a number of other research reports. ValuEngine lowered Intercept Pharmaceuticals from a sell rating to a strong sell rating in a report on Friday, February 2nd. Goldman Sachs Group lowered Intercept Pharmaceuticals from a neutral rating to a sell rating in a report on Wednesday, February 7th. Citigroup set a $74.00 target price on Intercept Pharmaceuticals and gave the company a hold rating in a report on Thursday, December 21st. Robert W. Baird restated an outperform rating and issued a $253.00 target price (down previously from $332.00) on shares of Intercept Pharmaceuticals in a report on Thursday, January 25th. Finally, Needham & Company LLC restated a hold rating on shares of Intercept Pharmaceuticals in a report on Wednesday, November 1st. Four investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have given a buy rating to the stock. The company has an average rating of Hold and an average target price of $128.75.
Intercept Pharmaceuticals (NASDAQ:ICPT) opened at $60.78 on Friday. Intercept Pharmaceuticals has a fifty-two week low of $51.05 and a fifty-two week high of $135.59. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 3.15. The firm has a market capitalization of $1,530.00, a P/E ratio of -4.23 and a beta of -2.13.
Several institutional investors and hedge funds have recently modified their holdings of ICPT. Senvest Management LLC purchased a new stake in shares of Intercept Pharmaceuticals during the third quarter valued at approximately $33,883,000. First Trust Advisors LP increased its position in Intercept Pharmaceuticals by 101.5% in the fourth quarter. First Trust Advisors LP now owns 605,454 shares of the biopharmaceutical company’s stock worth $35,371,000 after buying an additional 304,999 shares during the last quarter. Pinnacle Associates Ltd. purchased a new stake in Intercept Pharmaceuticals in the fourth quarter worth $12,577,000. Sarissa Capital Management LP purchased a new stake in Intercept Pharmaceuticals in the fourth quarter worth $10,649,000. Finally, Emerald Advisers Inc. PA purchased a new stake in Intercept Pharmaceuticals in the fourth quarter worth $9,497,000. 78.39% of the stock is owned by institutional investors.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.